FDA Approves KLYGEFA™ for Generalized Myasthenia Gravis

Innovations in Care

We provide programs and services that transform the lives of people affected by neuromuscular disease.

Servier Update on Sevasemten Clinical Program for Becker and Duchenne Muscular Dystrophy

December 1st, 2026
1:00 PM ET
Live, Virtual Webinar

Join Servier as they share updates from the topline data of the GRAND CANYON study for Becker muscular dystrophy and implications for future Becker and Duchenne trials

Register


Thank you to our supporter:

Servier logo